Cargando…
Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers
ARID1A is a tumour suppressor gene that is frequently mutated in clear cell and endometrioid carcinomas of the ovary and endometrium and is an important clinical biomarker for novel treatment approaches for patients with ARID1A defects. However, the accuracy of ARID1A immunohistochemistry (IHC) as a...
Autores principales: | Khalique, Saira, Naidoo, Kalnisha, Attygalle, Ayoma D, Kriplani, Divya, Daley, Frances, Lowe, Anne, Campbell, James, Jones, Thomas, Hubank, Michael, Fenwick, Kerry, Matthews, Nicholas, Rust, Alistair G, Lord, Christopher J, Banerjee, Susana, Natrajan, Rachael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065117/ https://www.ncbi.nlm.nih.gov/pubmed/29659191 http://dx.doi.org/10.1002/cjp2.103 |
Ejemplares similares
-
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)
por: Banerjee, Susana, et al.
Publicado: (2021) -
Definitive study shows no association between
ARID1A
mutation status and clinical outcome in endometriosis‐related ovarian cancers
por: Khalique, Saira, et al.
Publicado: (2022) -
ARID1A, NOTCH and WNT Signature in Gynaecological Tumours
por: Vaicekauskaitė, Ieva, et al.
Publicado: (2023) -
Significant Impacts of Increasing Aridity on the Arid Soil Microbiome
por: Neilson, Julia W., et al.
Publicado: (2017) -
ARID1B Immunohistochemistry Is an Important Test for the Diagnosis of Dedifferentiated and Undifferentiated Gynecologic Malignancies
por: Tessier-Cloutier, Basile
Publicado: (2023)